/PRNewswire/ – Edwards Lifesciences Corporation, the global leader in the science of heart valves and hemodynamic monitoring, today announced that Martha H. Marsh has been appointed to its board of directors.
Marsh served as the president and CEO of Stanford Hospital & Clinics for eight years, until her retirement in 2010. Prior to joining Stanford, Marsh served in hospital leadership positions at University of California Davis Medical Center, University of Pennsylvania Health System and Dartmouth-Hitchcock Medical Center.
“Martha is a welcome addition to our board of directors, which will benefit from her 30 years of experience and insight into serving patients in an increasingly complex and ever-evolving healthcare system,” said Michael A. Mussallem, Edwards’ chairman and CEO. “Martha’s deep knowledge and unique leadership will add a valuable perspective as our board considers the execution of our patient-focused innovation strategy.”
Currently, Marsh serves on the boards of directors of AMN Healthcare Services, Inc., and Owens & Minor Inc., a leading healthcare logistics company. She also served on the board of Thoratec Corp. until its Oct. 8 acquisition by St. Jude Medical, Inc.
Marsh has master’s degrees in public health administration and accounting from Columbia University and a bachelor’s degree in history from the University of Rochester.
Source: Edwards Lifesciences Corporation
After more than two years of leading LEO Pharma through a major transformation and a change of capital structure in a volatile environment during the global pandemic, the Board of Directors of LEO Pharma and President and CEO Catherine Mazzacco have jointly agreed that she will resign from her current role and leave the company on November 30, 2021.
Lonza and Bioqube Ventures, a European venture capital firm with a dual investment model including venture creation, have partnered to develop and manufacture biologics and small molecules. This is a five-year services agreement in which Lonza will provide advice and services to Bioqube Ventures’ portfolio companies.
UCB has granted to Chiesi global exclusive rights to develop, manufacture and commercialize zampilimab, a monoclonal antibody targeting transglutaminase 2 (TG2), an enzyme associated in fibrotic diseases. UCB will receive upfront payment, future milestone payments and net sales royalties.
